Identification of three hub genes related to the prognosis of idiopathic pulmonary fibrosis using bioinformatics analysis

Enze Wang1*, Yue Wang2*, Sijing Zhou3*, Xingyuan Xia1, Rui Han1, Guanghe Fei5 ©, Daxiong Zeng4 ©, Ran Wang1 ©

1. Department of respiratory and critical care medicine, the first affiliated hospital of Anhui medical university, Hefei 230022, China. 2. Department of Infectious Diseases, Hefei second people’s hospital, Hefei 230001, China. 3. Department of occupational medicine, Hefei third clinical college of Anhui Medical University, Hefei 230022, China. 4. Department of pulmonary and critical care medicine, Suzhou Dushu Lake Hospital, Suzhou, 215006, China. 5. Department of pulmonary and critical care medicine, Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University, Suzhou, 215006, China.

* These authors contributed equally to this work.

Corresponding authors: Daxiong Zeng Ph.D., Department of pulmonary and critical care medicine, Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University, Suzhou, 215006, China. Phone: 0512-65223637; Fax: 0512-65223637; E-mail: zengdxsz@126.com. Guanghe Fei Ph.D., Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Phone: 0551-62922913; Fax: 0551-62922913; E-mail: guanghefei@hotmail.com. Ran Wang Ph.D., Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Phone: 86-551-62922913; Fax: 86-551-62922913; E-mail: wangran@ahmu.edu.cn

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2022.03.29; Accepted: 2022.08.09; Published: 2022.08.15

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic respiratory disease characterized by peripheral distribution of bilateral pulmonary fibrosis that is more pronounced at the base. IPF has a short median survival time and a poor prognosis. Therefore, it is necessary to identify effective prognostic indicators to guide the treatment of patients with IPF.

Methods: We downloaded microarray data of bronchoalveolar lavage cells from the Gene Expression Omnibus (GEO), containing 176 IPF patients and 20 controls. The top 5,000 genes in the median absolute deviation were classified into different color modules using weighted gene co-expression network analysis (WGCNA), and the modules significantly associated with both survival time and survival status were identified as prognostic modules. We used Lasso Cox regression and multivariate Cox regression to search for hub genes related to prognosis from the differentially expressed genes (DEGs) in the prognostic modules and constructed a risk model and nomogram accordingly. Moreover, based on the risk model, we divided IPF patients into high-risk and low-risk groups to determine the biological functions and immune cell subtypes associated with the prognosis of IPF using gene set enrichment analysis and immune cell infiltration analysis.

Results: A total of 153 DEGs located in the prognostic modules, three (TPST1, MRVI1, and TM4SF1) of which were eventually defined as prognostic hub genes. A risk model was constructed based on the expression levels of the three hub genes, and the accuracy of the model was evaluated using time-dependent receiver operating characteristic (ROC) curves. The areas under the curve for 1-, 2-, and 3-year survival rates were 0.862, 0.885, and 0.833, respectively. The results of enrichment analysis showed that inflammation and immune processes significantly affected the prognosis of patients with IPF. The degree of mast and natural killer (NK) cell infiltration also increases the prognostic risk of IPF.

Conclusions: We identified three hub genes as independent molecular markers to predict the prognosis of patients with IPF and constructed a prognostic model that may be helpful in promoting therapeutic gains for IPF patients.

Key words: IPF, Prognosis, Bronchoalveolar lavage cells, Genes, Bioinformatics
Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) characterized by unexplained lung’s scarring and extensive remodeling\[1, 2\]. Although IPF is a rare disease, its incidence is increasing annually, and it primarily affects men aged > 50 years\[3\], which may be related to an aging population and increased awareness. Studies have shown that the incidence of IPF is approximately 2–30 cases per 100,000 person-years, with a prevalence of approximately 10–60 cases per 100,000 people\[4\]. Because of its rapid clinical progression, IPF usually has a poor long-term prognosis, with a median survival of only 2–3 years after diagnosis\[5, 6\]. Given the lack of effective molecular markers, the prognostic risk of IPF is often difficult to assess accurately. Therefore, it is necessary to develop predictive models for clinical treatment of IPF.

IPF is typically radiographically characterized by a peripheral distribution of bilateral fibrosis, more pronounced at the base, and it can be confirmed by lung biopsy when the diagnosis is uncertain\[7, 8\]. In recent years, some studies have used molecular biomarkers to assess the clinical course of IPF and achieved certain results\[9\]. However, most studies have used lung biopsies, which are invasive and not readily available for diagnosis. Bronchoalveolar lavage (BAL) is a technique in which sterile saline is pumped into the lungs, and the infusion is aspirated for analysis. It is a useful adjunct in the diagnostic evaluation for patients with ILD and can be used to identify infection and other inflammatory diseases\[10, 11\]. As a noninvasive and convenient detection method, BAL is more feasible for identifying molecular biomarkers from the gene expression profile of bronchoalveolar lavage cells (BLCs) to predict the prognosis of IPF.

In this study, we aimed to apply weighted gene co-expression network analysis (WGCNA)\[12\] to identify biomarkers associated with IPF prognosis in BLCs. First, we downloaded mRNA expression profiles and corresponding clinical information from the Gene Expression Omnibus (GEO). Then, WGCNA and differential expression analysis were used to identify prognostic gene set. Next, enrichment analysis was conducted to identify the important biological pathways affected. Finally, we constructed and verified prognostic models and compared the different pathways between different risk groups. We believe that our results may help with the diagnosis and treatment of IPF.

Figure 1. The flow chart of our study.
Methods

Dataset collection and processing

All data are available on the GEO dataset GSE70866, which contains 196 bronchoalveolar lavage fluid (BALF) samples consisting of 20 control individuals and 176 IPF patients\[13\]. Twenty control individuals and 112 IPF patients, analyzed using GPL14550, were divided into the training cohort, and the other 64 patients, analyzed using GPL17077, were divided into the testing cohort. Our study was not subject to review by the relevant ethics committee, because the information was obtained directly from a public database. Figure 1 shows the research process used in this study.

Screening of DEGs and construction of co-expression network

Firstly, we used R package “limma” for data normalization and identification of DEGs between IPF and healthy individuals in the training cohort\[14\]. The absolute value of log2 fold change (FC) was greater than 1, and the adjusted p-value (adj.P) was less than 0.05, as thresholds were used to define DEGs, which contained a total of 382 genes.

Co-expression modules were constructed using WGCNA, an analysis method to analyze gene expression patterns of multiple samples. WGCNA can cluster genes with similar expression patterns and analyze the association between modules and specific traits and phenotype. The gene expression levels of 112 IPF patients were sequenced according to the order of median absolute deviation, and the top 5000 genes were selected to construct the expression matrix. After seven outlier samples were deleted, standard scale-free network analysis was performed on the remaining 105 samples. When we defined 0.85 as the scale-free fitting index, the soft thresholding power was 5 (Figure 2D). The topological overlap matrix (TOM) was transformed by an adjacency matrix and corresponding dissimilarity (1-TOM) values were computed. We used dynamic tree cut method to identify the module. The lower limit of gene number of modules 30 and the height cut-off value 0.25 were selected as the criteria to distinguish modules. Pearson correlation analysis was used to assess the correlation between clinical characteristics (including age, sex, survival time and survival status) and gene modules. Prognostic modules were defined as modules that were significantly associated with both survival time and survival status.

Screening of prognostic hub genes

We selected target genes from gene sets included in both prognostic modules and DEGs. Genes significantly associated with prognosis were defined as DEGs with gene significance (GS) > 0.4 and weighted correlation index of module members (MM) > 0.7. Next, we performed further analyses of these genes in 112 IPF samples from the training cohort. Lasso Cox regression was conducted to search for key genes using the R package “glmnet”\[15\]. Hub genes were identified using multivariate Cox regression analysis to further confirm the best prognostic DEG signature.

Construction of prognostic model and nomogram

The risk score formula for IPF patients is as follows: \( \text{Risk Score} = \sum (\text{Each gene's expression} \times \text{Corresponding coefficient}) \). Based on the median risk score, we divided all patients into low- and high-risk groups, and time-dependent receiver operator characteristic (ROC) curves were used to test the risk score. A nomogram was constructed to predict the survival probability of IPF patients with age, sex, and hub genes using R package “rms”. The performances of the risk score and nomogram were verified in the testing cohort.

Enrichment analysis

The Metascape database and online tools were used to identify the functional annotation of all DEGs in the OS-related module\[16\]. Analysis thresholds were set as minimum counts > 3, enrichment factors > 1.5, and p-value < 0.01. Then, in order to search for the potential differential expression pathways in different risk groups, the gene set enrichment analysis (GSEA) was performed from R package “clusterProfiler”\[17\]. We chose the c5.go.v7.4.entrez.gmt and c2.cp.kegg.v7.4.entrez.gmt (from Molecular Signatures Database) as the reference gene sets and adj.P < 0.05 as the cut-off criteria.

Comparison of immune cell infiltration

To compare the heterogeneity of immune cell infiltration in patients with different risk groups, CIBERSORT algorithms were used to calculate the proportions of immune cell subtypes in the R platform\[18\]. Finally, Spearman analysis was used to evaluate the correlation between the degree of infiltration of immune cell subtypes and the expression levels of the prognostic hub genes.

Statistical analysis

Most analyses were performed using the software R4.1.1. If not otherwise specified, a p-value < 0.05 was considered statistically significant.
**Results**

**Demographic data**

In the training cohort, the mean age of the 112 IPF patients was 68 years, and that of the 20 healthy subjects was 61.9 years. The mean age of the 64 patients with IPF in the testing cohort was 68.3 years. IPF was most common in men in both the training and testing cohorts (83% men patients vs 17% women in the training cohort and 80% men patients vs 20% women in the testing cohort). Table 1 presents the demographic data used in this study.

**Identification of DEGs and modules related to the prognosis**

A total of 382 DEGs were identified in this dataset, which contained 208 upregulated and 174 downregulated genes. Figure 2(A) is a volcano map of all gene expressions, and Figure 2(B) shows a heatmap of the top 30 upregulated genes and the top 20 downregulated genes.

**Table 1. The demographic data of training and testing cohorts**

|              | Training cohort | Testing cohort |
|--------------|-----------------|----------------|
|              | Normal | IPF | N | 20 | 112 | 64 |
| Age(years)   | 61.9±7.6 | 68.0±10.0 | 68.3±8.5 |
| FVC predicted value (%) | 96±19 | 66.4±21.3 | 78±18 |
| Sex (%)     | Male | 16(80) | 93(83) | 51(80) |
|             | Female | 4(20) | 19(17) | 13(20) |
| Time to death (days) | NA | 698.1±553.4 | 701.4±451.3 |
| Survival status (%) | alive | NA | 36(32) | 40(63) |
|              | death | NA | 76(68) | 24(37) |

Data are presented as mean ± SD; FVC stands for forced lung capacity.
WGCNA analysis was performed on the differential gene expression profiles of 105 IPF patients with age, sex, survival time and survival status (Figure 2C). Twelve modules were identified by consensus (Figure 2E). The DEGs between the black and blue modules were most significantly associated with both survival time and survival status (Figure 2F). Therefore, we identified black and blue modules as key modules associated with prognosis, which consist of a total of 764 genes.

Identification of prognostic hub genes

Figure 3A showed a total of 153 DEGs contained in the prognostic modules. 38 genes with GS > 0.4 and MM > 0.7 were defined as important prognostic genes in the turquoise and brown modules (Table 2). TPST1, HS3ST1, TM4SF1, SOD3, MRVI1, and STAB1 were identified as key genes by Lasso Cox regression analysis (Figure 3B–C). Finally, according to the multivariate Cox regression analysis of six key genes, TPST1, MRVI1, and TM4SF1 were identified as hub genes (Figure 3D). The violin plot showed that the expression of TPST1, MRVI1, and TM4SF1 in the IPF group was visibly higher than that in the control group (Figure 3E–G). Kaplan-Meier (KM) survival curves showed that these three genes were closely related to the prognosis of IPF. Patients with high expression of three hub genes had shorter survival times and worse prognoses than those with low expression (Figure 3H–J).

Construction of prognostic model

Multivariate Cox regression was used to calculate the corresponding regression coefficients for TPST1, MRVI1, and TM4SF1, and the risk model was established accordingly. Figure 4(A) shows the formula for calculating the risk score. The 112 patients in the training cohort and 64 patients in the testing cohort were divided into high- and low-risk groups, based on the median risk score. KM survival curves in both cohorts showed that patients in the high-risk group had a more ominous prognosis than those in the low-risk group (Figure 4B–C). Time-dependent ROC curves were generated to detect the accuracy of prediction of the one-, two-, and three-year survival rates in both cohorts. The areas under the curve (AUC) were 0.862, 0.885, and 0.833, respectively, in the training cohort and, AUC in the testing cohort were 0.795, 0.782, and 0.794, respectively (Figure 4D–E).
Table 2. 38 genes associated with prognosis in the turquoise and brown modules

| Gene Symbol | Module Color | GS.OS     | p.GS.OS   | MM         | p.MM       |
|-------------|--------------|-----------|-----------|------------|------------|
| ADM         | blue         | -0.47864  | 2.41E-07  | 0.929084   | 1.53E-44   |
| CCL2        | blue         | -0.5694   | 2.32E-10  | 0.860735   | 5.69E-32   |
| HTRA1       | blue         | -0.50464  | 4.35E-07  | 0.849588   | 2.23E-30   |
| S100A12     | blue         | -0.44701  | 1.75E-06  | 0.846673   | 5.54E-30   |
| HAMP        | blue         | -0.41311  | 1.19E-05  | 0.844997   | 9.28E-30   |
| PLA2G7      | blue         | -0.50116  | 5.17E-08  | 0.844173   | 1.19E-29   |
| IER3        | blue         | -0.44526  | 1.94E-06  | 0.840484   | 3.64E-29   |
| FAM20A      | blue         | -0.52378  | 9.83E-09  | 0.835115   | 1.72E-28   |
| RGL1        | blue         | -0.46221  | 6.92E-07  | 0.834371   | 2.12E-28   |
| CCL7        | blue         | -0.51522  | 1.87E-08  | 0.82302    | 4.74E-27   |
| DYSF        | blue         | -0.41709  | 9.59E-06  | 0.819783   | 1.1E-26    |
| FAM198B     | blue         | -0.44424  | 2.04E-06  | 0.815487   | 3.31E-26   |
| MERTK       | blue         | -0.54821  | 1.42E-09  | 0.813605   | 5.3E-26    |
| CXCL1       | blue         | -0.43614  | 3.31E-06  | 0.81167    | 8.56E-26   |
| IL1R2       | blue         | -0.46862  | 4.62E-07  | 0.811009   | 1.01E-25   |
| TPST1       | blue         | -0.53923  | 2.94E-09  | 0.801859   | 8.95E-25   |
| STEAP4      | blue         | -0.40392  | 1.93E-05  | 0.798823   | 1.67E-23   |
| MRVI1       | blue         | -0.46954  | 4.35E-07  | 0.771104   | 6.46E-22   |
| STAB1       | blue         | -0.56304  | 4.05E-10  | 0.761484   | 4.12E-21   |
| SPPI        | blue         | -0.46175  | 7.12E-07  | 0.751431   | 2.6E-20    |
| ARAP3       | blue         | -0.40622  | 1.71E-05  | 0.744483   | 8.86E-20   |
| H5SF1T1     | blue         | -0.5059   | 3.69E-08  | 0.737415   | 2.96E-19   |
| MATK        | blue         | -0.45653  | 9.84E-07  | 0.732764   | 6.4E-19    |
| MMP7        | blue         | -0.40206  | 2.12E-05  | 0.723649   | 2.78E-18   |
| TM4SF19     | blue         | -0.51477  | 1.93E-08  | 0.713535   | 1.36E-17   |
| SH3RF1      | blue         | -0.45904  | 8.43E-07  | 0.701761   | 7.51E-17   |
| CYR61       | black        | -0.48367  | 1.72E-07  | 0.9291     | 1.73E-47   |
| MUC21       | black        | -0.42503  | 6.2E-06   | 0.896113   | 4.02E-38   |
| SFTPB       | black        | -0.50103  | 5.22E-08  | 0.888367   | 1.33E-36   |
| TM4SF1      | black        | -0.50926  | 2.9E-08   | 0.882091   | 1.89E-35   |
| CEACAM7     | black        | -0.52107  | 1.21E-08  | 0.85679    | 2.16E-31   |
| SOD3        | black        | -0.46694  | 5.14E-07  | 0.836578   | 1.13E-28   |
| MUC1        | black        | -0.41214  | 1.25E-05  | 0.817737   | 1.87E-26   |
| SFN         | black        | -0.44782  | 1.67E-06  | 0.811948   | 7.99E-26   |
| TUBB3       | black        | -0.43214  | 4.16E-06  | 0.800136   | 1.33E-24   |
| EMP1        | black        | -0.50598  | 3.67E-08  | 0.770788   | 6.88E-22   |
| PRSS8       | black        | -0.48262  | 1.85E-07  | 0.745873   | 6.96E-20   |
| S1PR3       | black        | -0.44095  | 2.5E-06   | 0.730392   | 9.43E-19   |

Functional annotation of prognosis-associated DEGs

To identify the potential biological pathways of genes in the prognostic modules, the software Metascape was used for enrichment analysis of all 153 prognosis-associated DEGs. Figure 5(A–C) shows the enriched top 20 prognosis-related pathways, and Table 3 shows the specific information of the top five pathways. We found that biological processes, such as the cell chemotaxis (GO:0060326, P < 0.001), secretory granule lumen (GO:0034774, P < 0.001), humoral immune response (GO:0006959, P < 0.001), extracellular matrix (GO:0031012, P < 0.001), and negative regulation of hydrolyase activity (GO:0051346, P < 0.001), were likely to influence disease progression in patients with IPF. GSEA was conducted in the different risk groups (Figure 5D–E). In contrast to the low-risk group, biological processes including cell chemotaxis, leukocyte chemotaxis, and migration were more active in the high-risk group. In addition, the pathways involved in high-risk groups included the cytokine-cytokine receptor interaction, focal adhesion, and ribosome.

Immune cell infiltration

In the enrichment analysis, we noticed that several pathways, such as humoral immune response, cytokine-cytokine receptor interaction, leukocyte chemotaxis, and migration, were closely related to immune processes. Therefore, we compared the proportions of different types of immune cells in different risk groups (Figure 6A). In contrast to the low-risk group, mast cells and natural killer (NK) cells had higher infiltration degrees in the high-risk group, whereas the infiltration degree of dendritic cells and activated CD4+ memory T cells were lower. Spearman correlation analysis was applied to study the association between immune cell subtypes and the expression of the hub genes (Figure 6B–M). The
expression of TPST1 was positively associated with activated mast cells \((r = 0.454, P < 0.001)\) but inversely related to resting dendritic cells \((r = -0.468, P < 0.001)\). The expression of MRVI1 was strongly correlated with activated mast cells \((r = 0.311, P < 0.001)\) and activated NK cells \((r = 0.302, P < 0.001)\), and with an increase in MRVI1, the degree of two kinds of cells infiltration was higher. Meanwhile, the expression of TM4SF1 was strongly related to activated mast cells \((r = 0.450, P < 0.001)\) and with an increase in TM4SF1, the degree of infiltration of activated mast cells was higher.

\[
\text{Risk Score} = 0.917 \times \text{TPST1} + 0.608 \times \text{MRVI1} + 1.029 \times \text{TM4SF1}
\]

Figure 4. Assessment of prognostic model performance. (A) The calculation formula of risk score. (B) Kaplan-Meier survival curve based on the median risk score in the training cohort. (C) Kaplan-Meier survival curve based on the median risk score in the testing cohort. (D) Time-dependent ROC curve for training cohort according to the prognostic model. (E) Time-dependent ROC curve for testing cohort according to the prognostic model. ROC, receiver operator characteristic; AUC, area under the curve.

Table 3. The top five biological pathways enriched by Metascape database

| Category              | Term                | Description                  | Log \(P\)          | Log(q-value)        | Symbols                                                                 |
|-----------------------|---------------------|------------------------------|--------------------|---------------------|-------------------------------------------------------------------------|
| GO Biological Processes | GO:0060326         | cell chemotaxis              | -10.35512264       | 6.7249463           | CCR3, GAS6, CXCL1, CXCL8, CCN3, S100A12, CCL2, CCL7, CCL13, SFTP D       |
| GO Cellular Components | GO:0034774         | secretory granule lumen      | -9.006327538       | 6.002149463         | CAMP, CDA, DEFA3, ECM1, F13A1, FCN1, FOLR3, GAS6, CXCL1, LIF1           |
| GO Biological Processes | GO:0006959         | humoral immune response      | -8.538668442       | 6.002149463         | C8A, C8B, CAMP, DEFA3, FCN1, CXCL1, CXCL8, PI3, S100A12, CCL2, CCL13, SFTP D, CXCL1 |
| GO Cellular Components | GO:0031012         | extracellular matrix         | -8.3298266         | 6.002149463         | CLC, ECM1, F13A1, FCN1, CCN1, LAMB1, MMP7, MMP9, MMP10, CCN3, PI3       |
| GO Biological Processes | GO:0051346         | negative regulation of hydrolase activity | -8.21907562       | 6.002149463         | CST5, ECM1, GAS6, SFPN, MMP9, PI3, SERPIN1, RG52, SPINK1, TIMP3          |
Construction of the prognostic nomogram

Considering that the age and sex of patients with IPF can also affect their prognosis, we constructed a nomogram with these significant clinical variables and three hub genes to quantify the 1-, 2-, and 3-year survival probabilities of patients with IPF (Figure 7A). Figure 7(B–D) shows the optimal prediction of the 1-, 2-, and 3-year survival rate based on the calibration curve. Finally, the time-dependent ROC curves of the risk module and nomogram were compared with the prediction efficiency in the training cohort (Figure 7E) and the results were validated in the testing cohort (Figure 7F). In general, there is little difference between the accuracy of two methods in predicting the both short-term and long-term survival rates.

Discussion

IPF is a chronic respiratory disease with an estimated incidence and prevalence of 0.09–1.30 and 0.33–4.51 cases per 10,000 persons[19]. Because of the short median survival time, many IPF patients experience varying degrees of delay in diagnosis and treatment, leading to poor prognosis[20]. Lamas et al. found that the median delay from the onset of clinical symptoms to the first in-hospital diagnosis was approximately 2.2 years, which was associated with a higher rate of death from IPF (P = 0.03)[21]. In the past few years, an increasing number of studies have focused on the cellular and molecular mechanisms of IPF, and progress has been made[22]. Several blood proteins, such as metalloproteases-7 (MMP7), SP-A,
and SP-D, can help distinguish IPF from other ILDs, even if they are not included in the guidelines [23-25]. In addition, some molecular markers, such as MMPs, tissue inhibitors of MMPs (TIMPs), and alpha-defensins, contribute to the assessment of mechanisms or biological pathways relevant to prognosis [26, 27].

The GSE70866 dataset is derived from the study of BLCs of patients in three independent IPF cohorts by Prasse et al. in 2019 [13]. In this study, they used nine gene signatures to construct prognostic models and compared the predictive performance of the models in different cohorts. The best prediction of survival time was in the Freiburg cohort (C-index, 0.73; 95% CI, 0.69–0.77), which was still slightly worse than our prediction model (C-index, 0.76; 95% CI, 0.73–0.79). On the one hand, in contrast to using one cohort (62 IPF patients and 20 control individuals) to construct the model by Prasse et al., we combined IPF patients from two cohorts on the basis of eliminating batch differences and standardized data and expanded the sample size in the training set. On the other hand, we used WGCNA to screen hub genes on the basis of differential expression analysis, which narrowed the selection of candidate genes and enhanced their association with survival time. In addition, some studies have used the same dataset to search for molecular markers correlated with the prognosis of IPF. Li et al. built a risk model using five ferroptosis-related genes for prognostic prediction in IPF [28]. Xia et al. used a method similar to ours to construct a four-gene signature risk model (C-index, 0.72; 95% CI, 0.66–0.77) [29]. However, they used...
follow-up time as a screening criterion for genes related to prognosis, which reduced the accuracy of their conclusions. In our study, the 1-, 2-, and 3-year AUC values of the time-dependent ROC curve based on the prognostic model were superior to those of previous models (0.862, 0.885, and 0.833 vs 0.737, 0.772, and 0.731 by Xia; 0.773, 0.774, and 0.752 by Li), thus demonstrating the potential applicability of our results.

The results of enrichment analysis indicated that the inflammatory response (such as cell chemotaxis and migration) and immune cell infiltration were key pathways affecting the disease progression of IPF patients and that biological processes mainly occurred in the extracellular matrix. Most pulmonary lung diseases are accompanied by persistent inflammation of the respiratory tract[30]. Alveolar and bronchial epithelial cells damaged by fibrosis release inflammatory mediators and chemokines, which trigger the formation of a provisional ECM and attract inflammatory cells to infiltrate lung tissues. Meanwhile, metalloproteinases and proinflammatory cytokines secreted by inflammatory cells also aggravate apoptosis and lung inflammation[31]. During this process, profibrotic cytokines and growth factors are secreted by activated lymphocytes and other cells; subsequently, fibroblasts are activated. Prolonged inflammatory stimulation leads to excessive accumulation of EMC components, exacerbating the progression of pulmonary fibrosis[32].

In recent years, a growing body of research has confirmed that innate and adaptive immune mechanisms play a necessary role in the progression of IPF, as confirmed in our study[32]. Neutrophils and macrophages are the primary immune cells in the pathogenesis of IPF, as reported in the literature[33-35]. Surprisingly, the results suggest that mast cells may also play an important role in the prognosis of IPF. Research by Veerappan et al. has suggested that the deficiency of mast cells in bleomycin-induced mouse models alleviates the decline in lung compliance, and significant fibrosis appears after transplantation of mast cells[36]. In general, the concentrations of histamine and trypsin secreted by mast cells are significantly increased in the BALF of IPF patients, which promotes fibroblast proliferation and synthesis of collagen fibers[33, 37]. However, the exact mechanism of mast cell and IPF progression remains to be explored.

![Figure 7. Construction of the prognostic nomogram.](image)

(A) Nomogram constructed by age, sex, and three hub genes. The calibration curves for prediction of 1- (B), 2- (C), and 3- (D) year survival rate. (E) Comparison of the time-dependent ROC curves for the nomogram and prognostic model in the training cohort. (F) Comparison of the time-dependent ROC curves for the nomogram and prognostic model in the testing cohort.
In our study, three hub genes (TPST1, MRVI1, and TM4SF1) were identified and found to be related to the prognosis of IPF. MRVI1, also known as IRAG, is the substrate of Inositol 1,4,5-triphosphate receptor-associated cGMP kinase, regulating intracellular IP3-induced calcium release through a NO/PRKG1-dependent mechanism. As reported, MRVI1 plays a key role in the progression of some types of cancer, such as endometrial carcinoma, ovarian carcinoma, neurofibromatosis, and involved in platelet activation and aggregation. Furthermore, activation of calcium channels in mast cells and fibroblasts are closely implicated to the progression of IPF and MRVI1 is likely to be a key factor affecting this process.

TM4SF1, a tumor-associated protein, is widely expressed in multiple human carcinomas, is localized at the surface of the cell membrane and late endocytic organelles, and plays a vital role in cell motility. CD63 is an important activation marker for mast cells and is highly expressed on the surface of activated mast cells. Several experiments have demonstrated that the expression of CD63 is inversely correlated with the motility of various cell types, while the overexpression of TM4SF1 can decrease the expression levels of CD63 on the cell surface, suggesting a potential mechanism for the activation and migration of mast cells. In addition, the expression of TM4SF1 in different tumors has different prognostic significances. For example, high expression of TM4SF1 in pancreatic ductal adenocarcinoma indicates a good prognosis, whereas it indicates a poor prognosis in lung cancer. The results of our study showed that in the lung tissues of IPF patients, high expression of TM4SF1 may lead to a poor prognosis by guiding mast cell migration and exacerbating the inflammatory process.

Protein-tyrosine sulfotransferase 1 (TPST1), a member of the protein sulfotransferase family, catalyzes the sulfuration of tyrosine residues within the acidic motif of polypeptides. Although the specific catalytic mechanism of the TPST1-induced tyrosine sulfation reaction is still unclear, it has been shown that TPST1 regulates immune and inflammatory responses by catalyzing the sulfation of tyrosine residues in some inflammatory mediators, such as chemokine receptors (i.e., CXCR4) and complement (i.e., C5a). TPST1 has been reported to be overexpressed in bladder cancer and nasopharyngeal carcinoma. Our study showed that TPST1 was highly expressed in the BALF of patients with IPF and was closely related to inflammatory cell infiltration (mast cells), suggesting that it could affect the prognosis of IPF.

Our study has some limitations. First, the sample size of the GSE70866 dataset was less than 200, while it had a larger sample size and more comprehensive clinical characteristics than most IPF datasets. Second, our study was limited to the inside of the dataset and lacked an effective external verification. Finally, the results of our study were obtained by the analysis of bioinformatics technology, and the specific mechanism by which hub genes affect the prognosis of IPF still needs to be confirmed by further experiments.

Conclusion

In summary, our study identified three hub genes (TPST1, MRVI1, and TM4SF1) in BLCs that are closely associated with the prognosis of IPF and created a new prognostic model. The results of our study revealed that inflammation and immune processes were the main pathways affecting the prognosis of IPF, and that there was a close relationship between the three hub genes and infiltration of mast cells. Our findings can provide guidance for the prognosis and treatment of patients with IPF.

Abbreviations

adj.P: adjusted P value; AUC: areas under the curve; BAL: bronchoalveolar lavage; BALF: bronchoalveolar lavage fluid; BLCs: bronchoalveolar lavage cells; DEGs: differentially expressed genes; ECM: extracellular matrix; GEO: gene expression omnibus; GS: gene significance; GSEA: gene set enrichment analysis; ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; MM: module members; NK: natural killer; ROC: receiver operator characteristic; WGCNA: weighted gene co-expression network analysis.

Acknowledgements

We acknowledge GEO database for providing their platforms and contributors for uploading their meaningful datasets.

Funding

This research was supported by the fund for Natural Science Foundation of China (No.81970051), Excellent Top Talent Cultivation Project of Anhui Higher Education Institutions (gxgxwfx2021014), A sub-project of the Anhui Medical University National first-class undergraduate specialty construction program (clinical medicine), Construction Project of Provincial Teaching Demonstration Course of Anhui Province (1364), scientific research fund from Anhui medical university (2020xkj257), and the Applied Medical Research Project of Hefei Health Commission (Hwk2021zd008).
Author Contributions

EW and YW analyzed the data and wrote the first draft. RW, GF, and DZ designed the study, proofread, and revised the submission. SZ and XX directed the statistical analyses of the data. RH retrieved documents and extracted data. All authors have read and agreed to the submitted version of the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. King TE, Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011; 378: 1494-61.
2. Remy-Morel FJ, Friling JW, Melgert BN, Olinga P, Hinrichs WJ. Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Mol Ther Methods Clin Dev. 2021; 20: 483-96.
3. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017; 389: 1941-52.
4. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017; 3: 17074.
5. Spall G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. Respirology. 2016; 21: 427-37.
6. Martinez FJ, Safarin S, Weycker D, Starko KM, Bradford WZ, King TE, Jr., et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005; 142: 963-7.
7. Krishna R, Chapman K, Ullah S. Idiopathic Pulmonary Fibrosis. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
8. Njok MS, Gujot J, Henket MA, Nivelles O, Thiry M, Desuefd F, et al. Sputum ecosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax. 2019; 74: 309-12.
9. Stainer A, Faverois P, Busnelli S, Cattalano M, Della Zoppa M, Marruchella A, et al. Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions. Int J Mol Sci. 2021; 22.
10. Patel PH, Antoine M, Ullah S. Bronchoalveolar Lavage. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
11. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. Bronchoalveolar Lavage Fluid Serves as Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis. Front Med (Lausanne). 2021; 8: 609359.
12. Xia Y, Lei G, Yang D, Luo H. Construction and validation of a bronchoalveolar lavage cell-associated gene signature for prognosis prediction in idiopathic pulmonary fibrosis. Int Immunopharmacol. 2021; 92: 107369.
13. Racanelli AC, Kikkers SA, Chei AMK, Cloonan SM. Autoimmune and inflammation in chronic respiratory disease. Autoimmunity. 2018; 14: 213-22.
14. Cabreira S, Maciel M, Herrera J, Nava T, Varga P, Gazzola M, et al. Essential role for the ATG8B protease and autophagy in bleomycin-induced pulmonary fibrosis. Autophagy. 2015; 11: 670-84.
15. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199-210.
16. Heukels P, Moor CC, von der Thüsen JH, Wijnenbeek MS, Kool M. Inflammation and immunity in IFP pathogenesis and treatment. Respir Med. 2019; 147: 79-91.
17. White ES, Lazar MH, Thannickal VJ. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol. 2003; 201: 343-54.
18. Shendker C, Collins SL, Powell JD, Horton MB. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021; 131.
19. Veerappan A, O'Connor NJ, Brajin J, Reid AC, Jung A, McGee D, et al. Mast cells: a pivotal role in pulmonary fibrosis. DNA Cell Biol. 2013; 32: 206-18.
20. Walls AF, Bennett AR, Godfrey RC, Holgate ST, Church MK. Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin Sci (Lond). 1991; 81: 183-8.
21. Oberheim Bush NA, Nedergraad M. Do Evolutionary Changes in Astrocytes Contribute to the Computational Power of the Hominid Brain? Neurochem Res. 2017; 42: 2577-87.
22. Schlossmann J, Desch M, IRAG and novel PKG targeting in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2011; 301: H1672-82.
23. Zhou Z, Xu YP, Wang LJ, Kong Y. miR-940 potentially promotes proliferation and metastasis of endometrial carcinoma through regulation of MRVI1. Biosci. 2020; 7: 202.
24. Wang K, Ju Q, Cao J, Tang W, Zhang J. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96: e7083.
25. Zhu C, Zhao YB, Kong LF, Li ZH, Kang J. [The expression and clinical role of KL-6 in serum and RALF in patients with different diffuse interstitial lung diseases]. Zhonghua Jie He Hu Xi Za Zhi. 2016; 39: 95-7.
26. Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, et al. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulm Med. 2020; 20: 64.
27. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 180: 167-75.
28. Li M, Wang K, Zhang Y, Fan M, Li A, Zhou J, et al. Ferroptosis-Related Genes in Bronchoalveolar Lavage Fluid Masters as Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis. Front Med (Lausanne). 2021; 8: 609359.
52. Chen Z, Liu G, Hossain A, Danilova IG, Belkov MA, Liu G, et al. A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival. Hereditas. 2019; 156: 24.

53. Xu J, Deng X, Tang M, Li L, Xiao L, Yang L, et al. Tyrosylprotein sulfotransferase-1 and tyrosine sulfation of chemokine receptor 4 are induced by Epstein-Barr virus encoded latent membrane protein 1 and associated with the metastatic potential of human nasopharyngeal carcinoma. PLoS One. 2013; 8: e56114.